290 related articles for article (PubMed ID: 26928421)
1. Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer.
Nappi RE; Cassani C; Rossi M; Zanellini F; Spinillo A
Minerva Ginecol; 2016 Oct; 68(5):602-12. PubMed ID: 26928421
[TBL] [Abstract][Full Text] [Related]
2. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
[TBL] [Abstract][Full Text] [Related]
4. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
[TBL] [Abstract][Full Text] [Related]
5. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH
Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.
Finch A; Narod SA
Maturitas; 2011 Nov; 70(3):261-5. PubMed ID: 21893388
[TBL] [Abstract][Full Text] [Related]
7. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
8. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report.
Shigehiro M; Kita M; Takeuchi S; Ashihara Y; Arai M; Okamura H
Jpn J Clin Oncol; 2016 Mar; 46(3):254-9. PubMed ID: 26685323
[TBL] [Abstract][Full Text] [Related]
9. Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives.
Arts-de Jong M; Harmsen MG; Hoogerbrugge N; Massuger LF; Hermens RP; de Hullu JA
Gynecol Oncol; 2015 Feb; 136(2):305-10. PubMed ID: 25560807
[TBL] [Abstract][Full Text] [Related]
10. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
[TBL] [Abstract][Full Text] [Related]
11. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
12. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
13. Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
D'Alonzo M; Piva E; Pecchio S; Liberale V; Modaffari P; Ponzone R; Biglia N
Clin Breast Cancer; 2018 Dec; 18(6):e1361-e1366. PubMed ID: 30122348
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk.
Arts-de Jong M; Maas AH; Massuger LF; Hoogerbrugge N; de Hullu JA
Crit Rev Oncol Hematol; 2014 Aug; 91(2):159-71. PubMed ID: 24529552
[TBL] [Abstract][Full Text] [Related]
16. A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
Yerushalmi R; Rizel S; Zoref D; Sharon E; Eitan R; Sabah G; Grubstein A; Rafson Y; Cohen M; Magen A; Birenboim I; Margel D; Ozlavo R; Sulkes A; Brenner B; Perry S
Isr Med Assoc J; 2016 Sep; 18(9):549-552. PubMed ID: 28471604
[TBL] [Abstract][Full Text] [Related]
17. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
Marchetti C; Iadarola R; Palaia I; di Donato V; Perniola G; Muzii L; Panici PB
Menopause; 2014 Jul; 21(7):763-8. PubMed ID: 24253485
[TBL] [Abstract][Full Text] [Related]
19. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Finch A; Evans G; Narod SA
Womens Health (Lond); 2012 Sep; 8(5):543-55. PubMed ID: 22934728
[TBL] [Abstract][Full Text] [Related]
20. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]